Humana is one of the largest Medicare Part D plan sponsors in the US and the operational backbone of the Medicare GLP-1 Bridge demonstration program that launches Wednesday July 1, 2026. CMS designated Humana as the single central processor for the Bridge, handling prior authorization, claims adjudication, and pharmacy payment for eligible Part D beneficiaries receiving Foundayo (orforglipron), Wegovy (injection and tablets), and Zepbound (KwikPen) at $50/month through December 31, 2027.
The central-processor role builds on Humana's existing administration of the Limited Income Newly Eligible Transition (LI NET) program, the Medicare program that provides immediate pharmacy access for low-income Part D beneficiaries while plan enrollment is being processed. The Bridge operational architecture mirrors LI NET in several ways: single processor, simplified prior authorization, beneficiary-eligibility verification through CMS data feeds, and pharmacy payment outside the standard Part D risk pool (Part D sponsors do not carry risk for eligible GLP-1 drugs under the Bridge).
Humana's broader obesity-coverage footprint matters because the company is also a major Medicare Advantage plan sponsor with its own utilization-management policies for GLP-1 drugs, and the policies set under the Bridge will inform how Part D sponsors structure coverage when the BALANCE Model rolls out in January 2027. Stories tagged here cover Humana's Bridge implementation, CMS-Humana coordination, the LI NET parallel, and the broader Medicare obesity-coverage policy track. See [[medicare-glp-1-bridge]], [[balance-model]], and [[cms]] for adjacent threads.
A Medical Daily report on July 6 found that eligible Part D beneficiaries are walking away from pharmacy counters without their GLP-1 prescriptions five days after the Bridge launched July 1. The rejections stem from a technical routing problem: when a pharmacy submits the claim through a patient's normal Part D plan, it is automatically denied. The fix is to route the claim through Humana's central processor using BIN 028918 and PCN MEDDGLP1BR, a detail many patients and pharmacists were unprepared for.
Day 2 of the Medicare GLP-1 Bridge demonstration ran through Thursday July 2, 2026 as the first prior-authorization submissions filed on Wednesday July 1 began flowing through Humana as central processor. CMS targets 72-hour turnaround on PA decisions, which puts the earliest Bridge-covered first fills at the pharmacy counter around Thursday July 3 to Friday July 4 for prescriptions submitted Wednesday. The wider first-fill wave is expected the week of July 6 as pharmacies complete Bridge-specific billing system setup using the Bridge BIN 028918 and PCN MEDDGLP1BR identifiers, and as prescribers gain familiarity with the eligibility-attestation workflow (BMI at start of GLP-1 therapy, absence of type 2 diabetes / moderate-to-severe OSA / MASH which would route to standard Part D instead). Humana's parallel role as the Limited Income Newly Eligible Transition (LI NET) program administrator provides operational infrastructure that CMS Medicare Director Chris Klomp cited on the Tuesday launch call as the reason the central-processor model can scale from Day 1 without a ramp-up window. Independent operational tracking through July will indicate whether the 72-hour PA target holds as volume builds.
The Centers for Medicare and Medicaid Services' Medicare GLP-1 Bridge demonstration program launched Wednesday July 1, 2026, opening prior-authorization submissions through Humana as central processor and activating the Bridge-specific pharmacy billing identifiers (BIN 028918, PCN MEDDGLP1BR). The program provides eligible Medicare Part D beneficiaries with $50/month access to four FDA-approved obesity drugs: Foundayo (orforglipron oral tablets, Eli Lilly), Wegovy injection (semaglutide, Novo Nordisk), Wegovy tablets (oral semaglutide in 1.5, 4, 9, and 25 mg strengths), and Zepbound KwikPen (tirzepatide single-dose autoinjector, Eli Lilly). CMS targets 72-hour prior-authorization turnaround. The Bridge runs through December 31, 2027 and transitions to the broader BALANCE Model launching January 2027 in Part D. It represents the first time Medicare has helped pay for drugs prescribed solely for obesity, breaking the 2003 Medicare Modernization Act exclusion that had barred obesity-only prescriptions from Part D coverage.
Becker's Payer Issues published a launch-day analysis titled '4 questions linger as CMS launches the Medicare GLP-1 Bridge' identifying operational uncertainties in the program even as the first prescriptions begin flowing. The four questions: (1) CMS could not confirm cost or enrollment projections on the launch call, leaving analyst modeling of program cost dependent on informal expectations from CMS Medicare Director Chris Klomp; (2) how quickly enrollment will build past Klomp's 'single-digit millions' framing given the manual prior-authorization workflow; (3) the absence of a formal appeals process within the Bridge itself (providers can resubmit eligibility forms repeatedly but there is no defined appeals track for denied prior authorizations); (4) whether manufacturer-negotiated pricing arrangements will hold at the $245 net price if utilization runs above expectations. The Bridge bypasses Part D sponsors entirely, in contrast to the voluntary Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth (BALANCE) Model launching January 2027 in Part D, which required sponsors to sign on. The Bridge's central-processor architecture through Humana handles all payment and prior-authorization traffic outside the standard Part D benefit structure.
The Medicare GLP-1 Bridge demonstration program launches Wednesday July 1, 2026 (one day from this digest), providing eligible Medicare Part D beneficiaries with $50/month access to Foundayo (orforglipron), Wegovy (injection and 1.5/4/9/25 mg tablets), and Zepbound KwikPen through December 31, 2027. Operationally, Humana opens its central-processor function for prior-authorization submissions and claims adjudication starting tomorrow; the Bridge-specific pharmacy billing identifiers (BIN 028918, PCN MEDDGLP1BR) become active for first fills. Walgreens published pharmacist-navigation guidance Tuesday flagging that store pharmacists will help Medicare patients verify eligibility (the three-tier BMI-and-comorbidity criteria walked through in this site's June 29 patient-guide insight), confirm Part D enrollment status, and submit the Bridge prior-authorization request to Humana through the dedicated workflow. CNN published a June 29 consumer explainer flagging that the program is the first time Medicare has paid for drugs prescribed solely for obesity. The Bridge runs in parallel with the broader BALANCE Model launching January 2027 in Part D, with the Bridge ending December 31, 2027 and beneficiaries transitioning to BALANCE.
Mainstream-media coverage of the Medicare GLP-1 Bridge demonstration intensified through the weekend ahead of Wednesday's July 1 launch. The Washington Post published 'Medicare is about to cover GLP-1 drugs for weight loss. Here's what to know' on June 29; CBS News ran a parallel explainer the same day; CNBC's June 28 piece flagged that a large share of eligible seniors may not yet know about the coverage expansion. The shared message across the three outlets: the program is the first time Medicare will help pay for drugs prescribed solely for obesity (rather than for diabetes, cardiovascular risk, or another approved indication), the $50/month copay applies to Foundayo (orforglipron tablets), Wegovy (injection and 1.5/4/9/25 mg tablets), and Zepbound KwikPen, the demonstration runs through December 31, 2027, and Humana acts as the single central processor for prior authorization and claims adjudication. CMS estimates several hundred thousand Medicare Part D beneficiaries will qualify under the three-tier BMI eligibility framework (BMI ≥35; BMI ≥30 with comorbid heart failure, uncontrolled hypertension, or chronic kidney disease; BMI ≥27 with prediabetes, prior MI, prior stroke, or peripheral artery disease). The Bridge transitions to the broader BALANCE Model launching January 2027 in Medicare Part D.
The week starting Monday June 29 stacks three federal regulatory milestones in three consecutive days. Monday: FDA's 503B GLP-1 exclusion public-comment window closes at 11:59 PM ET, finalizing the formal record on whether outsourcing facilities can continue compounding semaglutide, tirzepatide, and liraglutide. Tuesday June 30: registration for oral testimony at the July 23-24 Pharmacy Compounding Advisory Committee meeting closes (the meeting will vote 503A bulks list eligibility for BPC-157, KPV, TB-500, MOTS-c, Emideltide/DSIP, Semax, and Epitalon; the written-comment docket FDA-2025-N-6895 remains open through July 22). Wednesday July 1: the Medicare GLP-1 Bridge demonstration goes live for eligible Part D beneficiaries at $50/month for Foundayo (orforglipron), Wegovy (injection and 1.5/4/9/25 mg tablets), and Zepbound (KwikPen), with Humana serving as single central processor for prior authorization, claims adjudication, and pharmacy payment. The Bridge runs through December 31, 2027 and transitions to the broader BALANCE Model launching January 2027 in Medicare Part D. The three cutoffs collectively reshape the GLP-1 access architecture: branded direct supply expands through Medicare, bulk compounding through 503B narrows, and the non-GLP-1 503A peptide question goes to PCAC.
The Centers for Medicare & Medicaid Services' Medicare GLP-1 Bridge demonstration launches Wednesday July 1, 2026, five days from this digest's publication, providing eligible Medicare Part D beneficiaries with $50/month access to Foundayo (orforglipron), Wegovy (injection and 1.5/4/9/25 mg tablets), and Zepbound (KwikPen) for chronic weight management through December 31, 2027. Humana is the single central processor for prior authorization, claims adjudication, and pharmacy payment, operating outside of the standard Part D benefit's coverage and payment flow (Part D sponsors do not carry risk for eligible GLP-1 drugs under the Bridge). Two procedural details for prescribers: Medicare enrollment is not required to write a prescription or submit a prior-authorization request under the Bridge (the provider just cannot be on the Preclusion List), and prior-authorization requests will not be accepted or processed before July 1, when the prior-authorization form will be updated to include the fax submission number. Eligibility runs through three BMI tiers: BMI ≥35 with no additional requirement; BMI ≥30 with comorbid heart failure, uncontrolled hypertension, or chronic kidney disease; or BMI ≥27 with prediabetes, prior MI, prior stroke, or peripheral artery disease. The Bridge bridges to the broader BALANCE Model launching January 2027 in Medicare Part D.
The Centers for Medicare and Medicaid Services' GLP-1 Bridge demonstration launches Wednesday July 1, 2026 — 8 days from this digest's publication — providing eligible Medicare Part D beneficiaries with $50/month access to Foundayo (orforglipron), Wegovy injection, Wegovy pill, and Zepbound KwikPen for chronic weight management. The program runs through December 31, 2027 as a short-term bridge to the broader BALANCE Model (launching January 2027 in Medicare Part D). Humana, the current administrator of the Limited Income Newly Eligible Transition (LI NET) program, serves as the single central processor for prior authorization, claims adjudication, and pharmacy payment. CMS published the prior authorization fax form and prescriber/pharmacy educational materials on June 3, 2026. Eligibility requires BMI ≥30 (or ≥27 with comorbidities) and Part D enrollment. The launch arrives the same week as the Hims & Hers stock breakout and the FDA retatrutide compassionate-use disclosure — a coincidence that sharpens the peptide-access-equity debate as the broader US population continues to navigate $1,000+/month branded GLP-1 list prices.